Yasaman Mohammadi Kamalabadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasaman Mohammadi Kamalabadi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Adam G R Klotz
Department of Epidemiology and Biostatistics, Western University Schulich School of Medicine & Dentistry, London, Ontario, Canada
1 shared publicationAtefeh Jafari
Department of Epidemiology and Biostatistics, Western University Schulich School of Medicine & Dentistry, London, Ontario, Canada
1 shared publication- Danya Carroll
Schulich School of Medicine and Dentistry, Western University, London, ON N6G 2M1, Canada
1 shared publication Guangyong Zou
Department of Epidemiology and Biostatistics, Western University Schulich School of Medicine & Dentistry, London, Ontario, Canada
1 shared publication- Guangyong Zou
Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada
1 shared publication - Justyna Bartoszko
University of Toronto, Toronto, Canada
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by BMJ in BMJ Surgery
- Vol. 1 (1) , e000011
Outcome selection in clinical trials of pharmacologic haemostatic agents in surgery: systematic review
Introduction: Perioperative bleeding is an important contributor to morbidity and mortality after surgery, and numerous randomised trials have evaluated pharmacologic interventions to control its occurrence. However, outcomes used in these trials vary widely, which may affect trial design, interpretation, and clinical applicability. We aimed to summarise primary and non-primary outcomes used in randomised controlled trials evaluating pharmacologic haemostatic interventions in surgery. Research design and methods: This systematic review included trials published between 1 January 2015 and 26 December 2025 that enrolled at least 200 patients undergoing surgery and evaluated a pharmacologic haemostatic intervention. Descriptive analyses summarised the types and frequency of primary and non-primary outcomes, the distribution of sample sizes by primary outcome type, and risk of bias related to outcome selection. Results: Of 19 032 records screened, 87 trials (61 666 participants) met inclusion criteria. Most trials (66/87, 76%) used surrogate primary outcomes, including blood loss volume (46/87, 53%), haemostatic function (13/87, 15%) and haemoglobin/haematocrit change (7/87, 8%). Only 21 trials (24%) used clinical or management outcomes as the primary endpoint, including transfusion-related outcomes (11/87, 13%), composite outcomes (3/87, 3%) and other clinical outcomes (7/87, 8%) such as venous thromboembolism. Trials with clinical primary outcomes were larger than those with surrogate outcomes (median 657 (IQR 353–1880) vs 230 (210–325)). Common non-primary outcomes included blood transfusion (56/87, 64%), adverse events or complications (50/87, 57%) and haemoglobin/haematocrit change (45/87, 52%), whereas use of standardised bleeding definitions (4/87, 5%) was uncommon. Selective reporting was the most frequent source of high risk of bias (30/87, 34%). Conclusions: Most trials of pharmacologic haemostatic agents rely on surrogate primary outcomes, while clinically important outcomes are usually secondary. Greater use of patient-relevant endpoints may improve clinical applicability.
- 24 September 2026
- Published by BMJ in BMJ Surgery
- Vol. 1 (1) , e000011
Open AccessOutcome selection in clinical trials of pharmacologic haemostatic agents in surgery: systematic review
Introduction: Perioperative bleeding is an important contributor to morbidity and mortality after surgery, and numerous randomised trials have evaluated pharmacologic interventions to control its occurrence. However, outcomes used in these trials vary widely, which may affect trial design, interpretation, and clinical applicability. We aimed to summarise primary and non-primary outcomes used in randomised controlled trials evaluating pharmacologic haemostatic interventions in surgery. Research design and methods: This systematic review included trials published between 1 January 2015 and 26 December 2025 that enrolled at least 200 patients undergoing surgery and evaluated a pharmacologic haemostatic intervention. Descriptive analyses summarised the types and frequency of primary and non-primary outcomes, the distribution of sample sizes by primary outcome type, and risk of bias related to outcome selection. Results: Of 19 032 records screened, 87 trials (61 666 participants) met inclusion criteria. Most trials (66/87, 76%) used surrogate primary outcomes, including blood loss volume (46/87, 53%), haemostatic function (13/87, 15%) and haemoglobin/haematocrit change (7/87, 8%). Only 21 trials (24%) used clinical or management outcomes as the primary endpoint, including transfusion-related outcomes (11/87, 13%), composite outcomes (3/87, 3%) and other clinical outcomes (7/87, 8%) such as venous thromboembolism. Trials with clinical primary outcomes were larger than those with surrogate outcomes (median 657 (IQR 353–1880) vs 230 (210–325)). Common non-primary outcomes included blood transfusion (56/87, 64%), adverse events or complications (50/87, 57%) and haemoglobin/haematocrit change (45/87, 52%), whereas use of standardised bleeding definitions (4/87, 5%) was uncommon. Selective reporting was the most frequent source of high risk of bias (30/87, 34%). Conclusions: Most trials of pharmacologic haemostatic agents rely on surrogate primary outcomes, while clinically important outcomes are usually secondary. Greater use of patient-relevant endpoints may improve clinical applicability.
- Open Access
- 2 July 2026
- Published by Springer Nature in Perioperative Medicine
- Vol. 15 (1)
Definition, analysis, reporting, and interpretation of perioperative bleeding in randomized controlled trials: a methodological systematic review
Background: Perioperative bleeding is a common surgical complication and a frequently used outcome in randomized trials; however, its definition and analysis are not straightforward and have important implications for trial design, statistical power and interpretation of treatment effect. This review aimed to summarize how perioperative bleeding was defined in randomized controlled trials, along with sample size considerations, analytic approaches, and interpretation practices. Methods: On April 9th, 2025, we systematically searched the CENTRAL database for randomized trials in surgical settings published after January 2024 that evaluated perioperative bleeding as the primary outcome. Two reviewers independently screened and extracted data. Where appropriate, we categorized findings into conceptually similar domains and applied descriptive analysis. Results: We included 115 trials reporting 116 primary bleeding outcomes and identified 36 unique definitions, with assessment periods ranging from intraoperative to more than 30 days postoperatively. Volumetric or gravimetric measures were most common ( n = 46 [39.6%]), whereas patient-reported events ( n = 5 [4.3%]) and clinical management of blood loss ( n = 4 [3.4%]) were rare. Most trials reported a sample size calculation based on the primary outcome ( n = 90 [78.3%]), but over one-third lacked effect-size justification ( n = 34 [37.8%]). Analyses were predominantly parametric ( n = 69 [59.5%]), while a few adjusted for baseline covariates ( n = 18 [15.6%]). Interpretation in superiority trials relied mainly on statistical significance ( n = 49 [47.6%]). Among noninferiority trials, noninferiority was often claimed without prespecified margins ( n = 4 [33.3%]). Conclusion: Perioperative bleeding outcomes are defined and analyzed with high inconsistency. Standardized outcome definitions and reporting practices are needed in this field to improve trial comparability and clinical relevance.
- 2 July 2026
- Published by Springer Nature in Perioperative Medicine
- Vol. 15 (1)
Open AccessDefinition, analysis, reporting, and interpretation of perioperative bleeding in randomized controlled trials: a methodological systematic review
Background: Perioperative bleeding is a common surgical complication and a frequently used outcome in randomized trials; however, its definition and analysis are not straightforward and have important implications for trial design, statistical power and interpretation of treatment effect. This review aimed to summarize how perioperative bleeding was defined in randomized controlled trials, along with sample size considerations, analytic approaches, and interpretation practices. Methods: On April 9th, 2025, we systematically searched the CENTRAL database for randomized trials in surgical settings published after January 2024 that evaluated perioperative bleeding as the primary outcome. Two reviewers independently screened and extracted data. Where appropriate, we categorized findings into conceptually similar domains and applied descriptive analysis. Results: We included 115 trials reporting 116 primary bleeding outcomes and identified 36 unique definitions, with assessment periods ranging from intraoperative to more than 30 days postoperatively. Volumetric or gravimetric measures were most common ( n = 46 [39.6%]), whereas patient-reported events ( n = 5 [4.3%]) and clinical management of blood loss ( n = 4 [3.4%]) were rare. Most trials reported a sample size calculation based on the primary outcome ( n = 90 [78.3%]), but over one-third lacked effect-size justification ( n = 34 [37.8%]). Analyses were predominantly parametric ( n = 69 [59.5%]), while a few adjusted for baseline covariates ( n = 18 [15.6%]). Interpretation in superiority trials relied mainly on statistical significance ( n = 49 [47.6%]). Among noninferiority trials, noninferiority was often claimed without prespecified margins ( n = 4 [33.3%]). Conclusion: Perioperative bleeding outcomes are defined and analyzed with high inconsistency. Standardized outcome definitions and reporting practices are needed in this field to improve trial comparability and clinical relevance.
- Open Access
- 18 May 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (5) , 797
Community Engagement Within the Evaluation of Public Policies for Zoonotic Spillover Prevention: A Secondary Matrix Analysis
Despite the overall health, economic, and social costs of zoonotic spillover, its impacts are not felt equally around the globe. Engaging local communities in primary spillover prevention may help to better ensure equity is considered in research and policy-making activities. Our study aimed to gain an understanding of how and at what level community engagement (CE) has been incorporated into the evaluation of public policies for zoonotic spillover prevention. We conducted a secondary analysis on an existing dataset from a systematic review, beginning with a structured deductive content analysis. A secondary matrix of analysis was engaged using an adapted CE tool for screening the included articles based on their level of CE. We then characterized relevant themes based on the CE elements within the included articles. Of the 95 articles included, 55 had no level of CE reported. Among the included articles that had some level of CE, elements included the platforming of community consultation, community training for involvement in spillover prevention research, cultural and language considerations being engaged, community protection and awareness programmes for public health and biosecurity, and community-centered data collection processes being engaged. Our findings highlight the persistent equity gaps in appropriately engaging affected communities within the evaluation of public policies for spillover prevention.
- 18 May 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (5) , 797
Open AccessCommunity Engagement Within the Evaluation of Public Policies for Zoonotic Spillover Prevention: A Secondary Matrix Analysis
Despite the overall health, economic, and social costs of zoonotic spillover, its impacts are not felt equally around the globe. Engaging local communities in primary spillover prevention may help to better ensure equity is considered in research and policy-making activities. Our study aimed to gain an understanding of how and at what level community engagement (CE) has been incorporated into the evaluation of public policies for zoonotic spillover prevention. We conducted a secondary analysis on an existing dataset from a systematic review, beginning with a structured deductive content analysis. A secondary matrix of analysis was engaged using an adapted CE tool for screening the included articles based on their level of CE. We then characterized relevant themes based on the CE elements within the included articles. Of the 95 articles included, 55 had no level of CE reported. Among the included articles that had some level of CE, elements included the platforming of community consultation, community training for involvement in spillover prevention research, cultural and language considerations being engaged, community protection and awareness programmes for public health and biosecurity, and community-centered data collection processes being engaged. Our findings highlight the persistent equity gaps in appropriately engaging affected communities within the evaluation of public policies for spillover prevention.